LifeMD expands weight management program with launch of Eli Lilly’s Foundayo oral GLP-1
LifeMD (NASDAQ:LFMD), a leader in virtual primary care, announced on April 10, 2026, the addition of Eli Lilly’s newly approved oral weight-loss medication, Foundayo (orforglipron), to its comprehensive weight management program.










